(Q37881208)

24 August 2017

1 reference

title

Toward the development of a hepatitis E vaccine (English)

1 reference

24 August 2017

1 reference

1 reference

Saleem Kamili

1

1 reference

PubMed ID

21620908

24 August 2017

language of work or name

1 reference

18 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

161

1 reference

24 August 2017

1

1 reference

24 August 2017

93-100

1 reference

Long-term serological follow up and cross-challenge studies in rhesus monkeys experimentally infected with hepatitis E virus

24 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Cross-challenge studies in rhesus monkeys employing different Indian isolates of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Epidemic hepatitis E in Pakistan: patterns of serologic response and evidence that antibody to hepatitis E virus protects against disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Hepatitis E virus superinfection in patients with chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

DNA inoculation with a plasmid vector carrying the hepatitis E virus structural protein gene induces immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Hepatitis E vaccine: not a moment too soon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Hepatitis E virus and chronic hepatitis in organ-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

DNA vaccination against hepatitis E virus infection in cynomolgus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Hepatitis E and long-term antibody status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Incidence and severity of viral hepatitis in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Hepatitis E vaccine--ready for prime time?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

The expression, purification, and immunogenicity of a new chimeric virus-like particle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Amino-terminal epitopes are exposed when full-length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy-terminal epitopes are masked.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Oral administration of hepatitis E virus-like particles induces a systemic and mucosal immune response in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Protection of cynomolgus monkeys against HEV infection by oral administration of recombinant hepatitis E virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

DNA vaccines: an historical perspective and view to the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Purification and characterization of a recombinant hepatitis E protein vaccine candidate by liquid chromatography-mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Animal models of hepatitis A and E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Expression of a hepatitis E virus (HEV)-trpE fusion protein containing epitopes recognized by antibodies in sera from human cases and experimentally infected primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Perspectives of vaccination against hepatitis E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Safety and efficacy of a recombinant hepatitis E vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

In vitro infection and replication of hepatitis E virus in primary cynomolgus macaque hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

The two clinico-epidemiological forms of hepatitis E.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Hepatitis E epidemic, Uganda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Successful passive and active immunization of cynomolgus monkeys against hepatitis E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Augmentation of immune responses to hepatitis E virus ORF2 DNA vaccination by codelivery of cytokine genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Difference of T cell and B cell activation in two homologous proteins with similar antigenicity but great distinct immunogenicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Recombinant hepatitis E capsid protein self-assembles into a dual-domain T = 1 particle presenting native virus epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Fusion of C3d molecule with neutralization epitope(s) of hepatitis E virus enhances antibody avidity maturation and neutralizing activity following DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Hepatitis E virus. Advances in HEV biology and HEV vaccine approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis E virus structural protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

Expression and self-assembly of empty virus-like particles of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2011.05.008

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIRUSRES.2011.05.008

1 reference

24 August 2017

1 reference

PubMed ID

21620908